Predictive Efficacy of Modified Caprini Score and D-Dimer for the Evaluation and Management of Lower Extremity Venous Thrombosis Among Cardiothoracic Surgery Patients in Baghdad

Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Observational
SUMMARY

The goal of this observational study is to evaluate the predictive efficacy of the Modified Caprini Risk Assessment Score and D-Dimer in identifying and managing lower extremity venous thrombosis (LEVT) among cardiothoracic surgery patients in Baghdad. The main questions it aims to answer are: Does combining the Modified Caprini Score with D-Dimer improve the accuracy of predicting lower extremity venous thrombosis (LEVT) compared to using each tool independently? Can these tools effectively guide clinical decisions for lower extremity venous thrombosis (LEVT) prevention and management in this patient population? Participants will: Undergo risk assessment for lower extremity venous thrombosis (LEVT) using the Modified Caprini Score and have their D-Dimer levels measured during their hospital stay. Be monitored for clinical outcomes, including confirmed lower extremity venous thrombosis (LEVT) incidence, need for anticoagulation therapy, and complications such as pulmonary embolism or recurrent thrombosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Inpatients with a hospital stay over 3 days

• Written informed consent obtained from patients or their legal guardians.

• Availability for postoperative follow-up to assess outcomes like LEVT development or related complications.

Locations
Other Locations
Iraq
College of Medicine - Al-Nahrain University
RECRUITING
Baghdad
Contact Information
Primary
Abdul-Ilah R. Khamis
allaabed987@ced.nahrainuniv.edu.iq
+9647838571013
Backup
Luma K Mohammed, MBChB,FIBMS/CM
lumakmohammed@nahrainuniv.edu.iq
+964770225676
Time Frame
Start Date: 2025-01-20
Estimated Completion Date: 2025-07-30
Participants
Target number of participants: 112
Sponsors
Leads: Al-Nahrain University

This content was sourced from clinicaltrials.gov